Med-Fine Capital

Degron Therapeutics is a prominent platform company focused on discovering molecular glue degraders aimed at cancer treatment. The company specializes in developing small-molecule drugs that leverage its innovative protein degradation technology. By utilizing a molecular glue-based approach, Degron Therapeutics aims to create new therapeutic options that enhance treatment efficiency for patients with cancer. Through its research and development efforts, the company seeks to advance the field of targeted therapy and improve clinical outcomes.

CorrGene is an innovative company focusing on the research and development and production of new anti-cancer drugs and rare diseases with gene editing technology and cell therapy. The company was established by a group of cell and gene therapy experts, virologists, oncologists, hematologists and biopharmaceutical industry veterans. CorrGene was established in January, 2022 in Jiangsu, China.

Westlake Omics focuses on applying mass spectrometry-based proteomics and other Omics technologies to address pressing clinical needs. It is committed to making breakthroughs in precision medicine and drug R&D with an unwavering focus on critical issues that impact life and health. This vision is driven by AI-empowered high-throughput proteomic analysis of minute amounts of clinical specimens and Omics technologies, supported by technological innovation and multi-modal big data. It was founded in 2020 and is based in Hangzhou, Zhejiang, China.

AccuPulse is focused on the development of a pulsed electric field ablation (PFA) system designed to treat atrial fibrillation (A-fib). The company offers a comprehensive solution that includes both a PFA generator and specialized catheters for the pulse ablation of A-fib and tumors. By integrating advanced technologies, AccuPulse aims to enhance catheter localization and signal acquisition, while also improving the overall efficiency of interventional therapies that utilize radio frequency and cryotherapy. This innovative approach seeks to provide healthcare professionals and patients with a more effective and intelligent treatment option for managing A-fib and related conditions.

Allorion Therapeutics is a small molecule therapeutic development company dedicated to creating innovative treatments for cancer and autoimmune diseases. With operations in Natick, Massachusetts, and Guangzhou, China, the company specializes in developing mutant selective and isoform-specific drugs through non-conventional methods targeting established disease-related proteins. This approach aims to enhance drug efficacy and reduce the likelihood of resistance in patients, thereby improving therapeutic outcomes.

Provider of contract research organization (CRO) services to medical institutions. The company provides device preclinical inspection CRO services to medical equipment manufacturers and biomedical institutions, enabling clients to have reliable device preclinical inspection services.

Hangzhou Med-Vision Technology Co., Ltd. is a medical technology focusing on virtural reality, based in Hangzhou, China.

Nanjing Immunophage Biotech Co. Ltd., established in 2016 and based in China, focuses on developing innovative pharmaceutical therapies. The company operates a research and development center in the Pujiang High-Tech Park, Shanghai, where it specializes in creating first-in-class immune-regulating medicines. Immunophage is dedicated to addressing critical health challenges by developing drugs aimed at treating cancer, autoimmune diseases, and neurodegenerative disorders. Its therapeutic approach targets tumor growth inhibition and the reduction of Myeloid-derived suppressor cells, offering healthcare professionals more effective treatment options for patients.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Artivila Therapeutics is a pharmaceutical company established in 2018 and based in Shenzhen, China. The company specializes in biotechnology and is dedicated to improving patient outcomes through innovative drug discovery. Utilizing an AI-powered platform, Artivila focuses on developing new therapeutic solutions for neurodegenerative diseases, cancers, and autoimmune diseases. Its integrated approach aims to consistently and efficiently deliver first-in-class drug candidates, positioning Artivila at the forefront of pharmaceutical research and development.

Shenzhen VitaVitro Biotech Co., Ltd. is a biotechnology company specializing in assisted reproduction technology. Established in 2015 and headquartered in Shenzhen, China, the company offers a comprehensive range of products and services for assisted reproduction laboratories worldwide. Its offerings include cryopreservation solutions, various culture and flushing media, gamete buffer mediums, and labware, all designed to enhance the efficiency and success rates of in vitro fertilization (IVF) procedures. VitaVitro's focus is on addressing infertility challenges by providing integrated solutions that encompass the entire IVF process, from egg retrieval and freezing to embryo culture and transfer, ultimately aiming to optimize embryo quality and increase pregnancy rates for its clients. The company has expanded its presence with offices in Europe, America, and the Asia Pacific region.

Shanghai Hanyu Medical Technology Co., Ltd. specializes in the research and development of medical devices aimed at treating heart valve diseases. Established in 2016 and headquartered in Shanghai, with an additional office in Beijing, the company is recognized as one of the pioneering domestic firms in the development, production, and sale of transcatheter mitral valve repair devices. Hanyu Medical's flagship product, ValveClamp, is designed for minimally invasive interventions to address mitral valve regurgitation, enabling surgeons to close heart valves efficiently during procedures.

Zion is a leading drug discovery platform that develops "me-better" drugs that address true unmet needs.

ChosenMed is a Healthcare company based in Beijing.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Developer of an innovative targeted protein degradation technology intended to explore novel therapeutics. The company develops an innovative targeted protein degradation technology for the discovery and development of novel therapeutics, committing to creating transformative medicines for patients suffering from cancer and other serious diseases.

Guangzhou Excelmab Biomedical Technology Co., Ltd. is a biotechnology company based in Guangzhou, China, founded in 2016. The company specializes in the development of anti-tumor bispecific antibody drugs aimed at treating various types of cancer. Its products are designed for immuno-oncology applications, allowing healthcare professionals to offer more effective therapeutic options to cancer patients. ExcelMab focuses on creating innovative cancer treatments that not only target tumors but also aim to reduce associated symptoms, enhancing overall patient care in oncology.

Alebund Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative therapies for the treatment of renal diseases and related chronic conditions.

Suzhou MagAssist Medical Technology Co., Ltd. is a Chinese company specializing in the development of short and medium-term in vitro ventricular assist devices, commonly referred to as in vitro artificial hearts. Founded in 2016 and based in Suzhou, the company aims to provide innovative solutions for patients experiencing severe cardiovascular conditions, including those recovering from cardiopulmonary bypass and acute illnesses such as fulminant myocarditis and cardiac arrest. MagAssist focuses on integrating advanced fluid mechanics and magnetic suspension technology into its products to enhance compatibility with various blood types, thereby improving patient recovery outcomes. The company is recognized for its homegrown artificial heart technology, backed by a team of experts with extensive experience in artificial heart research and development.

Developer and researcher of advanced directional protein renaturation technology. The company uses advanced technologies such as high-throughput protein re-screening and purification technology platform, fixed point protein coupling design platform, high-throughput protein drug formulation development platform in their research, enabling the development of more effective protein-based drugs.

ZD MedTech, also known as Zhuo Dao Medical, specializes in the development of rehabilitation robots and intelligent rehabilitation solutions tailored to the clinical needs of Chinese medicine and its patients. The company boasts a domestic research and development team focused on creating advanced robotic assistive technology that enhances rehabilitation processes. Its offerings include high-end rehabilitation robots and exoskeleton training devices designed to facilitate upper limb recovery. By integrating rich training modes and effective human-computer interaction within its intelligent rehabilitation management system, ZD MedTech aims to improve patient outcomes and expedite rehabilitation treatments. Through ongoing innovation and adaptation to the evolving landscape of rehabilitation medicine, the company is committed to advancing the field and supporting the recovery journey of patients.

Immvira Co., Ltd. is a biopharmaceutical company based in Shenzhen, China, established in May 2015 by a team of renowned professors from various prestigious universities. The company specializes in the development of innovative anti-cancer therapies that utilize genetically engineered viruses. These therapies are designed to target cancer cells specifically and are enhanced by cancer-specific immune factors or chemotherapeutic agents. Immvira's product offerings include oncolytic herpes simplex viruses (oHSV) that encode interleukin-12 and anti-PD-1 antibodies, which can be delivered directly into tumor masses or in combination with systemic immune modulators. The company also explores auxiliary therapies and engineered viruses that can infect tumor cells with unique surface receptors.

Cherubs is a baby formula milk powder manufacturer.

Guangzhou Weimi Bio-Tech Co., Ltd., located in Guangzhou, China, is a biomedical company focused on research and development. It specializes in creating innovative in vitro diagnostic products for point-of-care testing. The company's offerings include advanced immunofluorescence chromatography products designed for a range of medical applications, such as inflammation detection, prenatal testing, cervical cancer diagnosis, and cardio-cerebral-vascular testing. Weimi Bio-Tech aims to provide reliable and effective immunochromatographic detection solutions to support medical practitioners in delivering quality healthcare.

Eccogene is a healthcare company focused on developing treatments for metabolism and immune-related diseases, particularly obesity and diabetes. The company specializes in disease biology, medicinal chemistry, and translational science to create immunological pharmaceuticals at the molecular level. Eccogene aims to address complex chronic diseases by providing a pipeline of metabolic drugs designed to enhance patient outcomes and improve overall health.

Shunzhi Technology is a Healthcare company.

Gaugene provides hematology testing instruments, reagents, and services for IVD users. Gaugene is a high-tech enterprise co-sponsored by core technology management backbones of well-known domestic IVD companies with rich management experience who master the industry’s top technologies.

ChosenMed is a Healthcare company based in Beijing.

Beijing Julu Medical Management Consultancy Co., Ltd. is a medical solution provider specializing in cardiac and pulmonary rehabilitation. Based in Beijing, China, the company is engaged in the research and development of clinical therapies aimed at improving the quality of life for patients with cardiac diseases. By focusing on rehabilitation therapies, Julu Medical addresses the needs of individuals requiring support in their recovery and management of cardiac and pulmonary health issues.

LYNK Pharmaceuticals is a biotechnology company based in Hangzhou, China, specializing in the development of small molecule drugs aimed at treating tumors and autoimmune diseases. Founded in 2017, the company focuses on the discovery and development of innovative medicines in the fields of oncology, immunology, and inflammatory diseases. Its business operations include new drug research, sales, and activities related to patent authorization and transfer.

Shanghai Hanyu Medical Technology Co., Ltd. specializes in the research and development of medical devices aimed at treating heart valve diseases. Established in 2016 and headquartered in Shanghai, with an additional office in Beijing, the company is recognized as one of the pioneering domestic firms in the development, production, and sale of transcatheter mitral valve repair devices. Hanyu Medical's flagship product, ValveClamp, is designed for minimally invasive interventions to address mitral valve regurgitation, enabling surgeons to close heart valves efficiently during procedures.

Beijing Mabworks Biotech Co., Ltd. is a biotechnology company based in Beijing, China, specializing in the research and development of gene-engineered antibody drugs. Founded in 2003, Mabworks focuses on the discovery, development, manufacturing, and commercialization of therapeutic antibodies. The company’s portfolio includes several products, such as MIL77, an Ebola treatment, MIL60, a biosimilar to the cancer drug Bevacizumab, and MIL62, which targets chronic lymphocytic leukemia. Additionally, Mabworks is involved in the development of innovative antibody drugs aimed at addressing various cancers and autoimmune diseases, leveraging advances in immunology and cancer biology.

Beijing Biosis Healing Biotechnology Co., Ltd. is a Chinese company founded in 2012, specializing in the research, development, production, and sales of biomaterial medical devices. The company focuses on regenerative medicine materials and implantable medical devices used in clinical surgery. Biosis Healing offers innovative products, including regenerative surgical biomaterials, implantable soft tissue repair mesh, and intelligent minimally invasive surgical instruments. A key product is their self-developed non-crosslinked Extracellular Matrix biomaterial, known as SIS material, which aids in the regeneration of tissue defects and provides effective solutions for tissue repair and functional regeneration following surgical procedures.

Beijing Mabworks Biotech Co., Ltd. is a biotechnology company based in Beijing, China, specializing in the research and development of gene-engineered antibody drugs. Founded in 2003, Mabworks focuses on the discovery, development, manufacturing, and commercialization of therapeutic antibodies. The company’s portfolio includes several products, such as MIL77, an Ebola treatment, MIL60, a biosimilar to the cancer drug Bevacizumab, and MIL62, which targets chronic lymphocytic leukemia. Additionally, Mabworks is involved in the development of innovative antibody drugs aimed at addressing various cancers and autoimmune diseases, leveraging advances in immunology and cancer biology.